1 Rothan HA, "The FDA-approved gold drug auranofin inhibits novel coronavirus(SARS-COV-2)replication and attenuates inflammation in human cells" 547 : 7-11, 2020
2 Sookoian S, "Repurposing drugs to target nonalcoholic steatohepatitis" 25 : 1783-1796, 2019
3 Sookoian S, "PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease" 18 : 6018-6026, 2012
4 Sookoian S, "PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ : the liver" 59 : 2068-2071, 2014
5 Sutton BM, "Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes" 15 : 1095-1098, 1972
6 Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies" 24 : 908-922, 2018
7 Sookoian S, "Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease" 218 : 378-385, 2011
8 Sookoian S, "Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease" 44 : 201-206, 2008
9 Pirola CJ, "Epigenetics factors in nonalcoholic fatty liver disease" 16 : 521-536, 2022
10 Fan C, "Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo" 5 : e1191-, 2014
1 Rothan HA, "The FDA-approved gold drug auranofin inhibits novel coronavirus(SARS-COV-2)replication and attenuates inflammation in human cells" 547 : 7-11, 2020
2 Sookoian S, "Repurposing drugs to target nonalcoholic steatohepatitis" 25 : 1783-1796, 2019
3 Sookoian S, "PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease" 18 : 6018-6026, 2012
4 Sookoian S, "PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ : the liver" 59 : 2068-2071, 2014
5 Sutton BM, "Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes" 15 : 1095-1098, 1972
6 Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies" 24 : 908-922, 2018
7 Sookoian S, "Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease" 218 : 378-385, 2011
8 Sookoian S, "Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease" 44 : 201-206, 2008
9 Pirola CJ, "Epigenetics factors in nonalcoholic fatty liver disease" 16 : 521-536, 2022
10 Fan C, "Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo" 5 : e1191-, 2014
11 Dufour JF, "Current therapies and new developments in NASH" 71 : 2123-2134, 2022
12 Hwangbo H, "Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro" 9 : 1040-, 2020
13 이승민 ; 고동희 ; Dae Won Jun ; 노윤진 ; Hyeon Tae Kang ; Ju Hee Oh ; Hyunsung Kim, "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways" 대한간학회 28 (28): 827-840, 2022
14 Shinha Han ; Hyunyul Kim ; 이영희 ; Myung Chul Lee ; Jeunghak Kwon ; 이종길 ; Youngcheon Song ; 이상진 ; 김광희 ; 김경제, "Auranofin Inhibits Overproduction of Pro-Inflammatory Cytokines, Cyclooxygenase Expression and PGE2 Production in Macrophages" 대한약학회 31 (31): 67-74, 2008
15 Roder C, "Auranofin : repurposing an old drug for a golden new age" 15 : 13-20, 2015
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
